| abstract |
The use of a compound of structural formula (I):n n or a pharmaceutically acceptable salt thereof or a prodrug thereof; wherein n R¹ represents a non-aromatic, non-fused 1-aza-bicyclic ring system selected from:n n n wherein the broken line represents an optional chemical bond; n the substituents R³ and R⁴ may be present at any position, including the point of attachment to the benzene ring, and independently represent hydrogen, C₁₋₄ alkyl, halo, C₁₋₄ alkoxy, hydroxy, carboxy or C₁₋₄ alkoxycarbonyl, or R³ and R⁴ together represent carbonyl; nand n R² and R¹¹ independently represent hydrogen, halo, -CF₃, -OR⁶, -NR⁶R⁷, -CN, -COR⁸, C₁₋₈ alkyl or C₂₋₈ alkenyl, provided that at least one of R² and R¹¹ is other than hydrogen, C₁₋₈ alkyl or C₂₋₈ alkenyl, or R² and R¹¹ taken together form a C₁₋₆ alkylenedioxy ring, wherein R⁶ is C₁₋₆ alkyl, R⁷ is hydrogen or C₁₋₆ alkyl, and R⁸ represents -OH, -OR⁶, -NHR⁷ or -NR⁶R⁷; nfor the manufacture of a medicament for treating glaucoma and/or for reducing intraocular pressure. |